Search research articles
Contact Us
Filters
Showing results (901-910 of 1,095) with videos related to
Page
of 110
Sort By:
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti, Edward Gane, Wai Kay Seto, et al.
Journal of Viral Hepatitis
|
August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry
Zobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.
Gastroenterologia Y Hepatologia
|
December 30, 2022
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Joan Martínez-Campreciós, Mar Riveiro-Barciela, Raquel Muñoz-Gómez, et al.
The New England Journal of Medicine
|
December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Patrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Gastroenterology
|
October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
E Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
Clinical Genitourinary Cancer
|
August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Clinical & Experimental Metastasis
|
February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
Journal of Hepatology
|
June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
George V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
Annals of Hepatology
|
May 29, 2015
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain
Javier Crespo, Moisés Diago, Joaquín Cabezas, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Page
of 110
Search research articles
Search
Showing results (901-910 of 1,095) with videos related to
Sort By:
Page
of 110
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti, Edward Gane, Wai Kay Seto, et al.
Journal of Viral Hepatitis
|
August 29, 2022
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry
Zobair M Younossi, Ming-Lung Yu, Mohamed El-Kassas, et al.
Gastroenterologia Y Hepatologia
|
December 30, 2022
Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
Joan Martínez-Campreciós, Mar Riveiro-Barciela, Raquel Muñoz-Gómez, et al.
The New England Journal of Medicine
|
December 5, 2008
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Patrick Marcellin, E Jenny Heathcote, Maria Buti, et al.
Gastroenterology
|
October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
E Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
Clinical Genitourinary Cancer
|
August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Clinical & Experimental Metastasis
|
February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
Journal of Hepatology
|
June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
George V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
Annals of Hepatology
|
May 29, 2015
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain
Javier Crespo, Moisés Diago, Joaquín Cabezas, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Page
of 110